Chardan Capital Lowers Zura Bio (NASDAQ:ZURA) Price Target to $10.00

Zura Bio (NASDAQ:ZURA) had its target price decreased by Chardan Capital from $12.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other analysts have also recently commented on ZURA. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.00.

Zura Bio Stock Up 1.5 %

Zura Bio stock opened at $1.36 on Wednesday. Zura Bio has a 12 month low of $1.07 and a 12 month high of $6.35. The company has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $2.75.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter. As a group, sell-side analysts expect that Zura Bio will post -0.65 EPS for the current year.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. bought a new position in shares of Zura Bio in the fourth quarter valued at approximately $27,000. Prudential Financial Inc. acquired a new position in Zura Bio in the 4th quarter valued at $28,000. Two Sigma Advisers LP bought a new position in Zura Bio in the 4th quarter worth $32,000. ProShare Advisors LLC acquired a new position in Zura Bio during the 4th quarter worth $35,000. Finally, XTX Topco Ltd bought a new stake in Zura Bio during the fourth quarter valued at about $44,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.